Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HTR1D | P28221 | 4/20 | 0.48 |
| ▸ | HTR1B | P28222 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6345252 | 0.98 | KDM4E (0.59) | DRD2DRD3KDM4EMAPTRAD52 | |
| Hydrochloric Acid SCHEMBL6343779 | 0.98 | KDM4E (0.59) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL29517510 | 0.87 | MAPT (0.61) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL189143 | 0.87 | MAPT (0.61) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL14320628 | 0.86 | MAPT (0.59) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL10155726 | 0.86 | KDM4E (0.46) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL5701472 | 0.85 | ALDH1A1 (0.57) | KDM4EMAPTRAD52ALDH1A1LMNA | |
| SCHEMBL24170260 | 0.83 | DRD2 (0.65) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL6973216 | 0.83 | KDM4E (0.53) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL6972479 | 0.83 | MAPT (0.53) | DRD2DRD3KDM4EMAPTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906934-B2 | Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors | Nerviano Medical Science S.R.L. (IT) | 2014-12-09 | — | — | US | claimed |
| EP-2004623-B1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-09 | — | — | EP | claimed |
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-22 | — | — | US | claimed |
| US-8263604-B2 | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-11 | — | — | US | claimed |
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| EP-2065380-A1 | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-03 | — | — | EP | claimed |
| US-20090099221-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-04-16 | — | — | US | claimed |
| EP-2004623-A1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-24 | — | — | EP | claimed |
| WO-2007110344-A1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-04 | — | — | WO | claimed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | claimed |
| US-6509340-B1 | These preparations can be employed as medicaments in human and veterinary medicine. Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) on the central nervous system. | MERCK PATENTGESELLSCHAFT (DE) | 2003-01-21 | — | — | US | claimed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | claimed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| US-20230227439-A1 | SPAK/OSR INHIBITORS AND METHODS OF USING SAME | YALE UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| CN-108623615-B | Macrocyclic derivatives of pyrazolo [3,4-d ] pyrimidin-3-one, pharmaceutical compositions and uses thereof | 上海迪诺医药科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| EP-0533266-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | DRD2 812/4885DRD3 1441/4885KDM4E 1086/4885 |
| US-20090099221-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | DRD2 3085/4885DRD3 3710/4885KDM4E 881/4885 |
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | DRD2 2858/4885DRD3 3531/4885KDM4E 872/4885 |
| US-20230227439-A1 | SPAK/OSR INHIBITORS AND METHODS OF USING SAME | OXSR1, VHL, TTK | DRD2 4834/4885DRD3 4830/4885KDM4E 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.